Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
Aprea Therapeutics (Nasdaq: APRE) closed an oversubscribed private placement, raising approximately $30 million in gross proceeds on March 31, 2026. The financing included pre-funded warrants to purchase ~37.2 million shares and warrants for ~37.2 million shares with a $0.683 exercise price expiring Dec 31, 2029.
The company said it will use net proceeds for general corporate purposes and R&D to support APR-1051 development, expand the ACESOT-1051 study, and enroll at least 50 patients in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer cohorts.
Aprea Therapeutics (Nasdaq: APRE) announced an oversubscribed private placement expected to raise approximately $30 million in gross proceeds before fees. The financing includes pre-funded warrants to buy ~37.2 million shares and warrants to purchase an additional ~37.2 million shares with a $0.683 strike.
The company expects to close on or about March 31, 2026, use proceeds for general corporate and R&D purposes, and believes the funds will extend cash runway into Q1 2028. Dose escalation completion for ACESOT-1051 is anticipated in Q2 2027.
Aprea (Nasdaq: APRE) reported a confirmed partial response (PR) to WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial at the 220 mg once-daily dose.
The patient with PPP2R1A-mutated endometrial cancer had a 50% reduction in target lesion size at first scan, a further 9.5% reduction at confirmation, and CA-125 fell from 362 U/mL to 40.2 U/mL. To date 24 patients received 10–220 mg; two PRs (one confirmed) and five stable disease responses reported. Dose escalation will progress toward 300 mg once daily in Q2 2026.
Aprea Therapeutics (Nasdaq: APRE) reported Q4 and full-year 2025 results and a corporate update on March 16, 2026. Key clinical progress includes two unconfirmed partial responses to oral WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer at 150 mg and 220 mg dose levels with marked CA-125 declines. ATRN-119 RP2D set at 1,100 mg while monotherapy enrollment is paused pending combination studies. Financials: cash of $14.6M (12/31/25), successful private placements raising ~$8.7M, Q4 net loss $2.5M ($0.32/share), 2025 net loss $12.6M ($1.93/share). Company expects cash runway into Q1 2027.
Aprea Therapeutics (Nasdaq: APRE) reported a second unconfirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051, observed at the 220 mg dose. The patient had a 50% target lesion reduction and an 87% drop in CA-125, with only Grade 1 adverse events.
To date, 22 patients have been treated across 10–220 mg. Both unconfirmed partial responses occurred in endometrial cancer with PPP2R1A mutations; confirmation and an additional trial update are expected in Q2 2026.
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:40 am EST. The presentation is virtual and will be webcast.
The webcast will be available for 90 days via the conference link or Aprea's Investors "News & Events" page. Investors may request 1:1 meetings through their Oppenheimer representative.
Aprea Therapeutics (Nasdaq: APRE) expanded its global patent estate in 2025 for its DNA damage response (DDR) oncology programs, with new patents granted in Australia and Japan and multiple pending applications worldwide.
Key points: lead WEE1 inhibitor APR-1051 is in Phase 1 (ACESOT-1051) and ATR inhibitor ATRN-119 is in clinical testing (ABOYA-119); core patents may provide protection into 2045 if pending applications issue.
Aprea Therapeutics (Nasdaq: APRE) announced on February 4, 2026 the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor following early clinical proof-of-concept for its WEE1 inhibitor APR-1051.
The company says Dr. Kennedy brings 20+ years of oncology clinical development, regulatory experience, and senior leadership to help advance dose escalation, refine patient selection, and support the DNA damage response (DDR) program toward key clinical and regulatory milestones.
Aprea Therapeutics (NASDAQ: APRE) reported early clinical proof-of-concept for single-agent WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 dose-escalation trial on Jan 29, 2026. An unconfirmed partial response was observed at the 150 mg dose with ~50% target lesion reduction and CA-125 fall from 732 to 70 U/mL.
Multiple patients showed stable disease and tumor reductions across 70 mg, 100 mg and 150 mg cohorts; 220 mg cohort is enrolling and dose escalation will continue to define the RP2D.
Aprea Therapeutics (Nasdaq: APRE) announced a private placement to sell 6,288,857 shares (or pre-funded warrants) plus warrants to purchase an additional 6,288,857 shares, with a combined effective offering price of $0.89 per unit, generating estimated gross proceeds of $5.6 million.
Warrants have a $0.765 exercise price, are exercisable immediately, and expire two years after the resale registration statement effectiveness; proceeds will fund R&D and to backfill patients in the ACESOT-1 APR-1051 study. Maxim Group is sole placement agent; close expected on or about Jan 30, 2026.